This article delves into Alzheimer’s disease (AD) as a neurocircuit dysfunction issue and assesses deep brain stimulation (DBS) as a potential treatment. It particularly examines fornix-targeted DBS (DBS-f), reporting phase 1/2 trials that show promising outcomes such as cognitive improvements, enhanced metabolism, and hippocampal growth. The study suggests further exploration into electrode placement and the impact of stimulation-induced autobiographical recall. It also compares DBS-f with nucleus basalis of Meynert (DBS-NBM) stimulation, identifying challenges and the need for research on optimal stimulation parameters. Additionally, the article considers alternative DBS targets and the potential of phase-3 DBS-f trials, along with closed-loop stimulation based on EEG biomarkers or hippocampal theta activity. It mentions recent FDA-approved therapies and other neuromodulation techniques, emphasizing the significance of imaging-based diagnosis and staging for circuit-targeted therapies due to AD’s heterogeneity. This research highlights the innovative approach of treating AD through neurocircuitry modulation, marking a significant shift from traditional treatments and opening new avenues for therapeutic interventions.